Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Gross Margin: 2013-2025

Historic Gross Margin for OptimizeRx (OPRX) over the last 13 years, with Q3 2025 value amounting to 67.2%.

  • OptimizeRx's Gross Margin rose 40900.0% to 67.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.31%, marking a year-over-year increase of 27100.0%. This contributed to the annual value of 64.45% for FY2024, which is 44700.0% up from last year.
  • Per OptimizeRx's latest filing, its Gross Margin stood at 67.2% for Q3 2025, which was up 40900.0% from 63.83% recorded in Q2 2025.
  • OptimizeRx's 5-year Gross Margin high stood at 68.15% for Q4 2024, and its period low was 54.54% during Q1 2021.
  • Its 5-year average for Gross Margin is 61.26%, with a median of 61.98% in 2024.
  • Per our database at Business Quant, OptimizeRx's Gross Margin skyrocketed by 86300bps in 2021 and then plummeted by -76800bps in 2023.
  • Quarter analysis of 5 years shows OptimizeRx's Gross Margin stood at 61.0% in 2021, then grew by 4bps to 63.37% in 2022, then fell by -1bps to 62.89% in 2023, then grew by 8bps to 68.15% in 2024, then fell by -1bps to 67.2% in 2025.
  • Its last three reported values are 67.2% in Q3 2025, 63.83% for Q2 2025, and 60.85% during Q1 2025.